"We are delighted to have been selected as one of the major centers to test this highly promising immunotherapeutic approach to treating individuals with NSCLC," said Dr. Julian Molina, principal investigator of the STOP Trial at Mayo Clinic in Rochester, Minnesota.
Lucanix(R) consists of four non-small cell lung cancer cell lines that have been genetically engineered to shut off their immune suppressive properties. These cell lines are then modified to block a molecule called transforming growth factor-beta (TGF-beta), which is commonly produced by cancer cells as a cloak against the body's natural immune system. When TGF-beta is blocked, the immune system can mount an anti-tumor response. The results of Phase II testing were published in the October 10, 2006 edition of the Journal of Clinical Oncology.
Studies to test the therapeutic vaccine in other types of cancer are also in progress. "NovaRx remains committed to developing whole cellbased therapeutic vaccines for any form of cancer in which this approach may significantly improve patient outcomes by either curing their disease entirely, or by stabilizing it over the course of their lives," said Justin Murdock, CEO and chairman of the board of NovaRx.
Founded in 1997, NovaRx Corp. is a clinical-stage biopharmaceutical
company dedicated to the discovery, development, and commercialization of
novel cell-based therapeutic vaccines for the treatment of cancer. The
company's 24,000 square foot headquarters in San Diego, CA, house corporate
offices and manufacturing operations. The proprietary core technology upon
which Lucanix(R) is based has been exclusively licensed to NovaRx on a
worldwide basis. Lucani
|SOURCE NovaRx Corporation|
Copyright©2008 PR Newswire.
All rights reserved